TMO

A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth lasting and the losses ending. How much has to go right for that price to hold.

Yahoo · 1d ago

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Yahoo · 2d ago

Dodge & Cox Fund, an investment management company, released its second-quarter 2026 investor letter for “Dodge and Cox Stock Fund”. You can download a copy of the letter here. U.S. equities achieved new all-time highs in Q2 2026, driven by a rally in the technology sector, led by memory semiconductor stocks. In Q2 2026, the […]

Yahoo · 3d ago

Opportunities include automated closed systems, AI-enabled quality control, single-cell and cell therapy workflows, precision medicine, advanced diagnostics and emerging-market expansion.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Cell Isolation/Cell Separation Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The market research report examines the global Cell Isolation/Cell Separation Market, which is projected to reach USD 6.97 billion in 2026 and grow a

Yahoo · 3d ago

Opportunities center on automated, standardized TDM kits integrated with AI dosing tools for antimicrobial stewardship, transplant care and precision medicine, especially in Asia-Pacific.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "TDM Reagent Kit Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global TDM Reagent Kit Market, projected to reach USD 2.87 billion in 2026 and grow at a CAGR of 15.84% to USD 6.96 billion

Yahoo · 3d ago

Thermo Fisher is rising Thursday, hitting an all-time high as strong Q2 results and raised FY guidance continue to support momentum.

Benzinga · 3d ago

Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.

Yahoo · 3d ago